Skip to main content
    P

    Protalix Biotherapeutics Inc (PLX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $2.69
    +0.08 (+3.26%)

    Market Cap: $210.29M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    51%(20/39)
    Avg Surprise
    +49.06%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.02
    Range$-0.05 - $0.01
    2 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.01-100.0%
    60d ago$-0.01-100.0%
    30d ago$-0.01-100.0%
    7d ago$-0.05+60.0%
    Current$-0.02
    Revenue Consensus
    $12M
    Range$12M - $13M
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.28
    Range$0.23 - $0.33
    2 analysts
    Revenue Consensus
    $45M
    Range$45M - $46M
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.28---
    Sep 26EST
    		-$-0.02---
    Jun 26
    Reported Aug 12
    		$0.05$-0.01+600.00%Beat+225.0%
    Mar 26
    Reported May 13
    		$0.22$-0.01+2300.00%Beat+540.0%
    Dec 25
    Reported Mar 18
    		$-0.07$0.04-300.00%Miss-177.8%
    Sep 25
    Reported Nov 13
    		$0.03$0.06-50.00%Miss+0.0%
    Jun 25
    Reported Aug 14
    		$-0.04$0.03-233.33%Miss-33.3%
    Mar 25
    Reported May 9
    		$-0.05$0.08-162.50%Miss+16.7%
    Dec 24
    Reported Mar 17
    		$0.09$0.07+28.57%Beat+228.6%
    Sep 24
    Reported Nov 14
    		$0.03$0.06-50.00%Miss+200.0%
    Jun 24
    Reported Aug 14
    		$-0.03$0.02-250.00%Miss-114.3%
    Mar 24
    Reported May 10
    		$-0.06$-0.02-200.00%Miss-20.0%
    Dec 23
    Reported Mar 14
    		$-0.07$-0.03-133.33%Miss+0.0%
    Sep 23
    Reported Nov 6
    		$-0.03N/A+57.14%Beat+57.1%
    Jun 23
    Reported Aug 7
    		$0.21$-0.04+625.00%Beat+290.9%
    Mar 23
    Reported May 4
    		$-0.05$-0.05+0.00%Beat+0.0%
    Dec 22
    Reported Feb 27
    		$-0.07N/A+53.33%Beat+53.3%
    Sep 22
    Reported Nov 14
    		$-0.07N/A+53.33%Beat+22.2%
    Jun 22
    Reported Aug 15
    		$-0.11$-0.18+38.89%Beat+56.0%
    Mar 22
    Reported May 16
    		$-0.05$-0.04-25.00%Miss+64.3%
    Dec 21
    Reported Mar 31
    		$-0.15$-0.11-36.36%Miss-1600.0%
    Sep 21
    Reported Nov 15
    		$-0.09$-0.12+25.00%Beat+35.7%
    Jun 21
    Reported Aug 16
    		$-0.25$-0.10-150.00%Miss-92.3%
    Mar 21
    Reported May 14
    		$-0.14$-0.17+17.65%Beat-240.0%
    Dec 20
    Reported Mar 30
    		$0.01N/A+112.50%Beat+0.0%
    Sep 20
    Reported Oct 29
    		$-0.14$-0.08-75.00%Miss+30.0%
    Jun 20
    Reported Aug 10
    		$-0.13$-0.20+35.00%Beat+74.0%
    Mar 20
    Reported Jun 1
    		$0.10N/A+133.33%Beat+120.0%
    Dec 19
    Reported Mar 12
    		$0.01N/A+101.59%Beat+102.7%
    Sep 19
    Reported Nov 7
    		$-0.20$-0.35+42.86%Beat+80.0%
    Jun 19
    Reported Aug 8
    		$-0.50$-0.30-66.67%Miss+37.5%
    Mar 19
    Reported May 6
    		$-0.50$-0.25-100.00%Miss+16.7%
    Dec 18
    Reported Mar 18
    		$-0.37$-0.45+17.78%Beat+38.3%
    Sep 18
    Reported Nov 7
    		$-1.00$-0.40-150.00%Miss-11.1%
    Jun 18
    Reported Aug 9
    		$-0.80$-0.40-100.00%Miss+25.9%
    Mar 18
    Reported May 9
    		$-0.60$-0.90+33.33%Beat-20.0%
    Dec 17
    Reported Mar 6
    		$-0.60$-0.60+0.00%Beat+52.8%
    Sep 17
    Reported Nov 8
    		$-0.90$-0.45-100.00%Miss-
    Jun 17
    Reported Aug 9
    		$-1.08$-0.35-208.57%Miss-
    Mar 17
    Reported May 10
    		$-0.50$-0.90+44.44%Beat-
    Dec 16
    Reported Mar 16
    		$-1.27$-1.10-15.45%Miss-

    Key Metrics

    Valuation
    P/E Ratio11.72EV/EBITDA7.82x
    Price/FCF28.11xFCF Yield3.56%
    Profitability
    Profit Margin23.50%Operating Margin23.50%
    ROE31.20%ROIC24.00%
    Financial Health
    Debt/Equity0.11xInterest CoverageN/A
    Current Ratio2.94xQuick Ratio1.91x
    Trading Statistics
    Beta-0.09Avg Volume889.91K
    52-Week High$3.1952-Week Low$1.60

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.72
    SMA 20$2.73
    SMA 50$2.61
    SMA 200$2.38
    EMA 10$2.71
    EMA 20$2.70
    EMA 50$2.61
    EMA 200$2.38

    MACD

    Line: 0.02Signal: 0.04Hist: -0.02

    ADX

    ADX: 23.9+DI: 17.1-DI: 20.1

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down60.0
    PSAR$2.80

    Bollinger Bands

    Upper Band$2.83
    Lower Band$2.63
    %B Position745%(Upper)
    Band Width0.34

    RSI (14-Day)

    Neutral
    50.7

    Momentum Oscillators

    Stoch %K39.4
    Stoch %D53.1
    Williams %R-55.8
    ROC (10d)0.6%
    Momentum0.01
    CCI (20d)-60.8
    MFI (14d)59.2

    Volatility Measures

    ATR (14d)$0.10(3.8%)
    StdDev (20d)0.05
    Hist Vol34.1%(Moderate)

    Volume Flow

    VWAP$2.69
    OBV24.6M
    AD Line3.6M
    CMF (20d)0.115

    Volume Metrics

    Avg Vol (20d)909.8K
    Vol Ratio1.3x
    VWMA (20d)$2.72

    Pivot Points

    R3$2.88
    R2$2.83
    R1$2.72
    Pivot Point$2.67
    S1$2.56
    S2$2.50
    S3$2.39

    Advanced Oscillators

    TSI7.63
    Ultimate Osc53.6
    KST50.11

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$19.90M$33.75M$9.12M$17.85M$15.66M$10.11M$18.22M$17.96M$13.47M$3.75M$10.49M$10.35M
    Cost of Revenue$7.76M$4.13M$4.62M$8.32M$5.87M$8.18M$3.89M$8.38M$9.46M$2.60M$8.86M$4.89M
    Gross Profit$12.13M$29.62M$4.50M$9.53M$9.79M$1.93M$14.33M$9.58M$4.02M$1.15M$1.63M$5.45M
    Operating Expenses$7.46M$8.48M$9.16M$7.40M$8.62M$6.08M$7.12M$5.59M$6.45M$6.00M$7.25M$7.34M
    R&D$4.35M$5.43M$5.63M$4.47M$5.99M$3.48M$4.12M$3.00M$2.96M$2.89M$3.10M$3.67M
    SG&A$3.11M$3.05M$3.53M$2.93M$2.62M$2.60M$3.00M$2.60M$3.48M$3.12M$4.14M$3.67M
    Operating Income$4.67M$21.15M$-4,658,000$2.13M$1.17M$-4,145,000$7.21M$3.99M$-2,427,000$-4,856,000$-5,615,000$-1,887,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$5,000$118,000$0$511,000$0$0$148,000$0$0$811,000$0
    Income Before Tax$4.86M$21.14M$-4,776,000$2.24M$661,000$-3,732,000$7.32M$3.84M$-2,272,000$-4,733,000$-6,426,000$-1,719,000
    Income Tax Expense$1.08M$2.82M$728,000$-116,000$497,000$-113,000$822,000$607,000$-69,000$-138,000$-382,000$133,000
    Net Income$3.78M$18.32M$-5,504,000$2.35M$164,000$-3,619,000$6.49M$3.24M$-2,203,000$-4,595,000$-6,044,000$-1,852,000
    EBITDA$5.27M$21.55M$-4,389,000$2.61M$1.02M$-3,386,000$7.65M$4.17M$-1,953,000$-4,411,000$-6,054,000$-1,354,000
    EBIT$4.86M$21.14M$-4,776,000$2.24M$661,000$-3,732,000$7.32M$3.84M$-2,272,000$-4,733,000$-6,426,000$-1,719,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PLX

    News

    A Hungarian fund manager reports a stake above 5% in Protalix BioTherapeutics (PLX).

    HOLD Alapkezelo Zrt., a Hungarian investment fund management company, has reported a beneficial ownership stake of 5.2% in Protalix BioTherapeutics, Inc. (PLX). This stake, amounting to 4,157,791 shares...

    Stock Titan•10/15/26•Neutral

    Protalix BioTherapeutics Grants 168,000 Derivative Securities to Executive Naos Yaron (AMEX: PLX)

    Protalix BioTherapeutics awarded 168,000 derivative securities to its Senior Vice President and Chief Operating Officer, Naos Yaron, on September 3...

    Kalkine Media•9/8/26•Neutral

    Protalix (PLX) Q2 2026 Earnings Call Transcript

    Protalix BioTherapeutics reported strong financial results for Q2 2026, driven by Elfabrio sales and a significant milestone payment. The company reiterated its full-year 2026 revenue guidance and maintained a debt-free...

    The Globe and Mail•8/19/26•Bullish

    Protalix BioTherapeutics Inc (PLX) (Q2 2026) Earnings Call Highlights: Net Income Surges to $3. ...

    Protalix BioTherapeutics Inc. reported a significant surge in net income for Q2 2026, reaching $3.8 million compared to $164,000 in Q2 2025...

    Yahoo! Finance Canada•8/12/26•Bullish

    Form 8K Protalix Biotherapeutics Inc For: 12 August By Investing.com

    This article reports that Protalix Biotherapeutics Inc. filed a Form 8K on August 12. The filing is a routine disclosure of significant events by publicly traded companies. The article provides the date of the filing...

    Investing.com Nigeria•8/12/26•Somewhat-Bearish

    PLX Valuation and Fair Value

    P/E
    11.7x
    Forward P/E
    55.9x
    EV/EBITDA
    7.8x
    P/FCF
    28.1x
    PEG
    -0.1x
    P/B
    3.0x
    See GNG's fair value

    PLX Profitability: Margins, ROIC and FCF

    Gross margin
    69.2%
    Operating margin
    23.5%
    Net margin
    23.5%
    ROIC
    24.0%
    ROE
    31.2%
    FCF margin
    9.5%
    FCF yield
    3.6%

    PLX Competitors

    CompanyTicker
    Owens & Minor IncOMI
    Alector IncALEC
    Larimar Therapeutics IncLRMR
    ProQR Therapeutics BVPRQR
    MacroGenics IncMGNX
    Cartesian Therapeutics Inc.RNAC
    Keros Therapeutics IncKROS
    Pro-Dex IncPDEX

    Sector: Healthcare

    PLX Bull Case vs Bear Case

    Bull case

    • PLX earns a 24.0% return on invested capital.
    • PLX has a 23.5% net profit margin.
    • PLX grew quarterly revenue 27.1% year over year.

    Bear case

    • PLX beat EPS estimates in 37.5% of its last 8 reported quarters.

    PLX Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    266.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.02
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About PLX

    Does PLX pay dividends?

    Protalix Biotherapeutics Inc (PLX) does not currently pay a regular dividend.

    What is PLX's P/E ratio?

    Protalix Biotherapeutics Inc has a price-to-earnings (P/E) ratio of 11.72.

    What is PLX's market cap?

    Protalix Biotherapeutics Inc (PLX) has a market capitalization of $210.29M with a current stock price of $2.69.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In